GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akebia Therapeutics Inc (STU:AX9) » Definitions » Goodwill-to-Asset

Akebia Therapeutics (STU:AX9) Goodwill-to-Asset : 0.27 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Akebia Therapeutics's Goodwill for the quarter that ended in Dec. 2024 was €56.4 Mil. Akebia Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was €210.7 Mil. Therefore, Akebia Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 was 0.27.


Akebia Therapeutics Goodwill-to-Asset Historical Data

The historical data trend for Akebia Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Goodwill-to-Asset Chart

Akebia Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.11 0.17 0.24 0.27

Akebia Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.26 0.27 0.29 0.27

Competitive Comparison of Akebia Therapeutics's Goodwill-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Goodwill-to-Asset falls into.



Akebia Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Akebia Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill to Asset (A: Dec. 2024 )=Goodwill/Total Assets
=56.387/210.74
=0.27

Akebia Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill to Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=56.387/210.74
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akebia Therapeutics  (STU:AX9) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Akebia Therapeutics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics Business Description

Traded in Other Exchanges
Address
245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Headlines

No Headlines